EPHA6

Across TCGA pan-cancer cohorts, EPHA6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EPHA6 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher EPHA6 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated EPHA6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, SKCM, and PRAD are the cancer types where EPHA6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.952	0.605	.002	24	view →
SKCM	OS	Median	All	0.964	0.849	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	III,IV	0.387	0.669	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EPHA6–UCEC (DFS)

Open the UCEC breakdown →